"Bold Goals for U.S. Biotechnology and Biomanufacturing"
The White House has announced new goals and priorities to promote biotechnology and biomanufacturing in the US, with cell therapy as a focus area to promote human health. This Administration aims to improve the effectiveness of cell therapies within five years and increase their manufacturing scale within 20 years to expand accessibility.
Last September, President Biden signed an executive order launching the “National Biotechnology and Biomanufacturing Program”. The new report, “Bold Goals for U.S. Biotechnology and Biomanufacturing”, is in line with the program and outlines 49 specific goals across five areas, including
solving climate change,
improving food and agriculture innovation,
enhancing supply chain resilience,
promoting human health,
and promoting cross-disciplinary development.
The report is authored by a team from the White House Office of Science and Technology Policy, the US Department of Energy, the US Department of Agriculture, the US Department of Commerce, the US Department of Health and Human Services, and the US National Science Foundation.
Some of the report's goals include（1）demonstrating and deploying sustainable and cost-effective routes for transforming bio-based feedstocks into polymers that can be recovered and reused,（2）increasing the production of climate-smart feed and biofuels,（3）reducing the greenhouse gas emissions of biofuels by 50%,（4）increasing the production of chemical demand from biomanufacturing by at least 30% through sustainable and cost-effective methods, and（5）advancing cell therapy, AI-driven biologic drug production, and gene editing technologies.
Bold goals for the U.S. bioeconomy include, for example:
Climate: In 20 years, demonstrate and deploy cost-effective and sustainable routes to convert bio-based feedstocks into recyclable-by-design polymers that can displace more than 90% of today’s plastics and other commercial polymers at scale.
Food and Agriculture: By 2030, reduce methane emissions from agriculture, including by increasing biogas capture and utilization from manure management systems, reducing methane from ruminant livestock, and reducing methane emissions from food waste in landfills, to support the U.S. goal of reducing greenhouse gas emissions by 50% and the global goal of reducing methane emissions by 30%.
Supply Chain: In 20 years, produce at least 30% of the U.S. chemical demand via sustainable and cost-effective biomanufacturing pathways.
Health: In 20 years, increase the manufacturing scale of cell-based therapies to expand access, decrease health inequities, and decrease the manufacturing cost of cell-based therapies 10-fold.
Cross-Cutting Advances: In 5 years, sequence the genomes of one million microbial species and understand the function of at least 80% of the newly discovered genes.
Reaching these bold goals will require progress in other areas beyond R&D to ensure that innovation can lead to safe, effective, and equitable products in our daily lives which grow the bioeconomy across all of America and with our partners globally. In forthcoming reports and plans, departments and agencies will outline recommendations and steps that are underway to advance the following:
Data for the bioeconomy – establishing a Data Initiative to ensure that high-quality, wideranging, easily accessible, and secure biological data sets can drive breakthroughs for the U.S. bioeconomy.
Domestic biomanufacturing infrastructure – expanding domestic capacity to manufacture all the biotechnology products we invent in the United States and support a resilient supply chain.
Workforce development – growing training and education opportunities for the biotechnology and biomanufacturing workforce of the future.
Regulatory clarity and efficiency – improving the clarity and efficiency of the regulatory process for biotechnology products to help ensure products come to market safely and efficiently.
Biosafety and biosecurity – creating a Biosafety and Biosecurity Innovation Initiative to reduce risks associated with advances in biotechnology and biomanufacturing.
International engagement R&D – pursuing cooperation through joint research projects and data sharing, while mitigating risks and reaffirming democratic values.
The National Institutes of Health has set specific goals for cell therapy, including increasing the efficacy of cell therapies, enhancing their accessibility and affordability, and establishing a comprehensive understanding of cell therapy manufacturing.
The US government expects that by the end of this century, biotechnology could account for over a third of global manufacturing output, worth nearly $30tn, and has allocated more than $2bn to its “National Biotechnology and Biomanufacturing Program”.
Fresh Wind Biotechnologies, Inc. is developing innovative and potent cellular immunotherapies to enhance cancer patient's every day experiences. Founded in 2020, our incredible team of scientists, clinicians, bioinformaticians and business development experts have worked tirelessly to bring our company to the forefront of the fight against cancer.
We dedicate our resources to develop and to commercialize highly effective and safe personalized cancer treatment. We focus on integration of high-throughput platforms, state-of-art data science and engineering, and innovative cellular therapy technologies to advance precision oncology.